Systemic treatment of malignant pleural mesothelioma: New agents in clinical trials raise hope of relevant improvements

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 171-181

  Christoph, Daniel C ^a   Eberhardt, Wilfried E E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Clinical trials; Cytotoxic compounds; Mesothelioma; Targeted drugs

Indexed keywords

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894076590     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000053     Document Type: Review

References (46)

1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17:260-271
2. Astoul P, Roca E, Galateau-Salle F, Scherpereel A. Malignant pleural mesothelioma: From the bench to the bedside. Respiration 2012; 83:481-493
3. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591-1603
4. Takahashi K. Emerging health effects of asbestos in Asia. Proceedings of the Global Asbestos Congress, Tokyo, 19-21 November 2004: 2. abstract
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644
6. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881-6889
7. Gelvez-Zapata SM, Gaffney D, Scarci M, Coonar AS. What is the survival after surgery for localized malignant pleural mesotheliomä Interact Cardiovasc Thorac Surg 2013; 16:533-537
8. König JE, Tolnay E, Wiethege T, Müller KM. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 1999; 435:8-12
9. Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA, et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 1996; 178:151-160
10. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999; 81:54-61
11. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30:2509-2515
12. Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012; 77:567-571
13. Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013; 109:552-558
14. Scherpereel A, Mazieres J, Margery J, et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. International Mesothelioma Interest Group (IMIG) Meeting Boston; 2012. IB.5
15. Scherpereel A, Mazieres J, Astoul P, et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II-III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma: Preliminary results of the phase II trial. International Mesothelioma Interest Group (IMIG) Meeting Kyoto; 2010. S06-4
16. Dubey S, Jänne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010; 5:1655-1661
17. Papa S, Popat S, Shah R, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol 2013; 8:783-787
18. Laurie SA, Gupta A, Chu Q, et al. Brief report: A phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol 2011; 6:1950-1954
19. Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 2012; 7:1449-1456
20. Jahan T, Gu L, Kratzke R, et al. Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2012; 76:393-396
21. Buikhuisen WA, Vincent AD, Scharpfenecker MM, et al. A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma (MPM): Clinical results of a single-center trial. J Clin Oncol 2013; 31 (suppl; abstr 7528
22. Campbell NP, Kunnavakkam R, Leighl N, et al. Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium. Lung Cancer 2012; 78:76-80
23. Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011; 6:1938-1945
24. Fujimoto J, Wistuba II, Moon J, et al. Biomarker results from a phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905). J Thorac Oncol 2013; 8 (suppl 2):P1.14-009
25. Nowak AK, Brown C, Millward MJ, et al. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer 2013; 81:422-427
26. Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagine-glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010; 28:2604-2611
27. De Vincenzo F, Rossoni G, Santoro A, et al. NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM). J Clin Oncol 2011; 29 (suppl; abstr 7089
28. Gregorc V, Rossoni G, Lambiase A, Bordignon C. Phase III trial of NGR-HTNF plus Best Investigator's Choice (BIC) versus placebo plus BIC in previously treated patients with malignant pleural mesothelioma (MPM). International Mesothelioma Interest Group (IMIG) Meeting Boston; 2012. P1.10
29. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109
30. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-2189
31. Rischin D, Bibby DC, Chong G, et al. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: A phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res 2011; 17:5152-5160
32. Fennell DA, McDowell C, Busacca S, et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7:1466-1470
33. O'Brien ME, Gaafar RM, Popat S, et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer 2013; 49:2815-2822
34. Szlosarek PW, Steele J, Sheaff M, et al. A randomised phase II trial of pegylated arginine deiminase in patients with malignant pleural mesothelioma. J Thorac Oncol 2013; 8 (suppl 2):MO09.02
35. Szlosarek PW, Luong P, Phillips MM, et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 2013; 31:e111-e113
36. Maltzman JD, Wallin BA, Gupta A, et al. Exposure-response relationship of amatuximab (AMA) in combination with pemetrexed and cisplatin (P/C) in patients with unresectable pleural mesothelioma. J Thorac Oncol 2013; 8 (suppl 2):O22.05
37. Reck M, Hassan R, Jahan T, et al. A multicenter phase II clinical trial of the chimeric antimesothelin monoclonal antibody amatuximab in combination with chemotherapy for frontline therapy of malignant pleural mesothelioma: Updated clinical outcomes and correlative studies. Ann Oncol 2012; 23 (suppl 9):1522PD
38. Stevenson J, Kindler H, Schwed D, et al. Phase II trial of antitransforming growth factor-beta (TGFb) monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma (MPM). International Mesothelioma Interest Group (IMIG) Meeting Boston; 2012. IVB.3
39. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-Arm, phase 2 trial. Lancet Oncol 2013; 14:1104-1111
40. Kindler HL, Di Pietro A, Robbins PB, et al. A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma. J Thorac Oncol 2013; 8 (suppl 2):P2.14-015
41. Garland LL, Ou SH, Moon J, et al. SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). J Clin Oncol 2012; 30 (suppl; abstr 7083
42. Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008; 27:1189-1197
43. Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw 2012; 10:42-47
44. Remon J, Lianes P, Martínez S, et al. Malignant mesothelioma: New insights into a rare disease. Cancer Treat Rev 2013; 39:584-591
45. Haas AR, Sterman DH. Malignant pleural mesothelioma: Update on treatment optionswith a focus on novel therapies. Clin ChestMed 2013; 34:99-111
46. Nowak AK. Chemotherapy for malignant pleural mesothelioma: A review of current management and a look to the future. Ann Cardiothorac Surg 2012; 1:508-515